Iroxanadine

DB05444ExperimentalSmall molecule

BRX-235 (iroxanadine) is a a novel small molecule synthesized by Biorex, Hungary that acts as a cardioprotective agent. It induces phosphorylation of p38 SAPK, which plays an important role in... EC function plays a central role in vascular diseases (e.g. atherosclerosis, restenosis, diabetic angiopathies, microvascular angina, peripheral arterial disease).

Mechanism: BRX-235 induces phosphorylation of p38 SAPK, which plays an important role in EC (endothelial cell) homeostasis.
Curator reviewed
Primary indication: Investigated for use/treatment in atherosclerosis and vascular diseases as a cardioprotective agent.Curator reviewed
Formula / weight: C₁₄H₂₀N₄O · 260.3348 g/mol (avg)

Resolves to

Compound

UNII6K69EJ1DL1CAS276690-58-5ChEMBLCHEMBL2107433PubChem6421776

Structure

InChIKeyQWVRTSZDKPRPDF-UHFFFAOYSA-NSMILESC(C1CONC(=N1)C1=CN=CC=C1)N1CCCCC1

Targets

P0DMV9HSPA1BP0DMV8HSPA1A

What you can answer from here — as of March 06, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Iroxanadine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account